Company Overview of Tinea Pharmaceuticals, Inc.
Tinea Pharmaceuticals, Inc., a biopharmaceutical company, develops products for the treatment of onychomycosis or fungal infections of the toenail and nail bed. Its Luliconazole is a topical antifungal agent against a range of pathogens, including Trichophyton rubrum, Trichophyton mentagrophytes, and yeasts. The company was formerly known as Topica Pharmaceuticals, Inc. and changed its name to Tinea Pharmaceuticals, Inc. in September 2010. The company was founded in 2004 and is based in Palo Alto, California.
435 Tasso Street
Palo Alto, CA 94301-1555
Founded in 2004
Key Executives for Tinea Pharmaceuticals, Inc.
Chief Executive Officer, President and Director
Senior Vice President of Clinical Development and Operations
Senior Vice President of Regulatory & Quality
General Counsel and Secretary
Compensation as of Fiscal Year 2015.
Tinea Pharmaceuticals, Inc. Key Developments
Tinea Pharmaceuticals, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013
Oct 4 13
Tinea Pharmaceuticals, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013 . Venue: The Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, United States.
TOPICA Pharmaceuticals, Inc. Announces Results from Phase IIb/III Onychomycosis Study
Sep 20 13
TOPICA Pharmaceuticals, Inc. has announced interim safety and mycologic susceptibility results from the ongoing Phase IIb/III SOLUTION study evaluating 10% Luliconazole solution. With 334 patients enrolled in the clinical trial and approximately 50 patients having completed the study's protocol at week 52, Luliconazole Solution is very well tolerated topically and shows no signs of systemic side effects at this point in the trial. As part of the SOLUTION Study, clinical isolates were collected from 184 patients in the study and tested for mycologic susceptibility to TOPICA's 10% Luliconazole Solution. When clinical isolates (96.2% were T. rubrum) collected from patients participating in the SOLUTION Study were tested, luliconazole had a minimum inhibitory concentration (MIC90) of 0.0005 mcg/ml, confirming that the molecule is the most potent anti-fungal against the relevant fungi that cause onychomycosis. 'The blinded data show that when the active or vehicle control have been applied for up to 48 weeks in either of the two dosing regimens being evaluated by the clinical trial, they exhibit excellent local tolerability, a good clinical laboratory safety profile and an unremarkable safety profile based on the number of reported adverse events to date in the study.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries